Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of des-O-methyllasiodiplodin in preparation of medicament for treating kidney diseases

A technology of methylmadiprene and kidney disease, which is applied in the application field of de-O-methylmadiprene in the preparation of medicines for treating kidney disease, and can solve the problems of no research reports on the therapeutic effect of kidney disease , to achieve a good therapeutic effect

Inactive Publication Date: 2013-04-17
NANJING CHILDRENS HOSPITAL AFFILIATED TO NANJING MEDICAL UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese patent 200810200074.4 discloses benzomacrocyclic lactone compound (3R)-de-O-methylmadipredrine, its derivatives and their preparation methods and uses; 201110079284.4 discloses 3R-de-O-methyl The use of mateprenol in the preparation of drugs for the prevention or treatment of depression; but there is no research report on its therapeutic effect on kidney disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of des-O-methyllasiodiplodin in preparation of medicament for treating kidney diseases
  • Application of des-O-methyllasiodiplodin in preparation of medicament for treating kidney diseases
  • Application of des-O-methyllasiodiplodin in preparation of medicament for treating kidney diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1: The pharmacological effect of des-O-methylmadiprene on nephrotic syndrome

[0020] 1. Experimental materials

[0021] Aminonucleoside puromycin was purchased from Sigma Company of the United States; SuperScript III RNase H-Reverse Transcriptase Kit was purchased from Invitrogen Company of the United States; goat anti-nephrin, podocin antibody, horseradish peroxidase-labeled anti-goat and mouse secondary antibodies were purchased from American Santa Cruz company.

[0022] 2. Experimental method

[0023] 1. Animal model preparation and experimental grouping: 40 male SD rats, weighing 80-100 grams. Randomly divided into 5 groups, normal control group, model group, de-O-methylmaidepredrine (DML) low-dose treatment group, de-O-methylmaudepredrine (DML) high-dose treatment group and de-O-methylmaudepredrine (DML) control group, 8 rats in each group (n=8). Normal control group: intraperitoneal injection of normal saline; model group, des-O-methylmaideprene lo...

Embodiment 2

[0038] Example 2 Pharmacological effects of des-O-methylmaudeprene (DML) on mesangial proliferative glomerulonephritis.

[0039] 1. Experimental materials

[0040] 40 healthy male SD rats, 4 weeks old, weighing about 160g, were purchased from the Experimental Animal Center of Jiangsu Province; complete Freund's adjuvant, FITC-labeled goat anti-rabbit IgG and Schiff reagent were purchased from Sigma Company of the United States, proliferating cell nuclear antigen ( PCNA) and monocyte chemoattractant-1 (MCP-1) monoclonal antibody were purchased from Sant Cruz Company in the United States, horseradish peroxidase-labeled goat anti-rabbit IgG, normal goat serum blocking solution, DAB chromogenic reagent were purchased from Beijing Zhongshan Biotechnology Company.

[0041] 2. Experimental method

[0042] 1. Preparation of anti-rat thymocyte antiserum (ATS): 4-week-old SD rats, take their thymus and prepare a certain concentration of single thymocyte suspension, mix with complete F...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of des-O-methyllasiodiplodin in preparation of a medicament for treating kidney diseases. Experimental studies show that the des-O-methyllasiodiplodin has a good effect of protecting the kidney, has an obvious inhibiting effect on pathological symptoms such as urinary protein sum rise, foot process fusion and disappearance, podocyte injury, glomerular nucleated cell sum rise, mesentery area and glomerular area enlargement, crescent formation and proliferating cell nuclear antigen (PCNA) and methyl cyclopentenolone 1 (MCP-1) expression, and has a good prevention and treatment effect on multiple kidney diseases. Obvious adverse response is avoided in the experimental process, and the des-O-methyllasiodiplodin is expected to be developed into a new-generation safe and effective medicament for treating the kidney diseases.

Description

technical field [0001] The present invention relates to des-O-methylmaidepredrine compounds, in particular to the application of des-O-methylmaudepredrine in the preparation of medicines for treating kidney diseases. Background technique [0002] Kidney disease is a serious threat to human life and health. Tens of millions of patients die of kidney disease every year. Primary nephrotic syndrome is a common urinary system disease in pediatrics. The main clinical manifestations are proteinuria, hypoproteinemia, high Lipidemia and different degrees of edema, the number of children who die each year due to primary nephrotic syndrome is on the rise. It is reported abroad that the incidence rate of people under the age of 16 is about 15.7 / 100,000. Children hospitalized in hospitals in some provinces and cities in my country According to statistical data, nephrotic syndrome accounts for about 21-31% of children with urological diseases. If active and effective treatment is not adopte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P13/12A61P29/00
Inventor 张爱华黄松明
Owner NANJING CHILDRENS HOSPITAL AFFILIATED TO NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com